PDD Holdings Inc. American Depositary Shares vs BIO-TECHNE Corp — how do they compare? PDD Holdings Inc. American Depositary Shares trades at $78.7 (market cap $111.74B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: PDD Holdings Inc. American Depositary Shares is far larger — about 9.8× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while PDD Holdings Inc. American Depositary Shares pays none. Which is the better fit depends on your goals.
| PDD | TECH | |
|---|---|---|
Market Cap | $111.74B | $11.37B |
Volume | 4,029,869 | 3,153,511 |
Sector | Consumer Cyclical | Health |
52-Week High | $138.13 | $72.61 |
52-Week Low | $73.30 | $43.31 |
Enterprise Value | $44.39B | $11.40B |
Typical Hold Time | — | 63 Days |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
Latest headlines on both assets
PDD Holdings is a multinational commerce group that owns and operates a portfolio of businesses. Its sourcing, logistics, and fulfillment network supports those businesses and their commerce operations.
Read more on PDD →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →